Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2019

View Archived Issues

Staph toxins' DARC arts: Targeting blood vessels

Alternative energy for metabolic brain disorder

H3 Biomedicine publishes preclinical pharmacokinetics and metabolism data on H3B-6545

Imbrium Therapeutics and TetraGenetics collaborate to develop novel biologic therapeutics for pain

TG Therapeutics initiates first-in-human study of its anti-CD47/CD19 bispecific antibody TG-1801

Acetylation by aspirin can attenuate autoimmunity

LY-3295668 demonstrates efficacy in RB1mut cancer models

Eribulin liposomal formulation well tolerated in patients with solid tumors

Nicotinamide N-methyltransferase inhibitor enhances aged muscle regeneration

Prion protein-binding monoclonal antibodies synthesized at New York University

Northwestern University presents beta-glucocerebrosidase activators

Bristol-Myers Squibb discovers sphingosine 1-phosphate receptor 1 agonists

New PD-1/PD-L1 interaction inhibitors patented by ChemoCentryx

Southeast University describes antibodies targeting the HPV16 E6 oncoprotein

New generation of SARDs for the treatment of advanced prostate cancer

Targeting DEFA1/DEFA3 ameliorates sepsis severity in mice

Alkermes begins ARTISTRY 2 study of subcutaneous ALKS-4230 in advanced solid tumors

Grants to support evaluation of Radspherin in colorectal cancer

Immatics Biotechnologies and Roche to test IMA-101 plus Tecentriq in cancer

FunPep gains Australian clearance for phase I/IIa study of FPP-003

MHRA clears Nuformix to begin human pharmacokinetic studies with NXP-001

Immunic initiates phase II study of IMU-838 for relapsing-remitting MS

Eidos initiates pivotal phase III study of AG-10 in ATTR-CM

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...